Most read article(s)

You have access
Molecular, Behavioral, and Physiological Consequences of Methamphetamine Neurotoxicity: Implications for Treatment
Anna Moszczynska and Sean Patrick Callan

Journal of Pharmacology and Experimental Therapeutics September 2017, 362 (3) 474-488; DOI: https://doi.org/10.1124/jpet.116.238501
You have access
The Dual Amylin- and Calcitonin-Receptor Agonist KBP-042 Works as Adjunct to Metformin on Fasting Hyperglycemia and HbA1c in a Rat Model of Type 2 Diabetes
Sara T. Hjuler, Sofie Gydesen, Kim V. Andreassen, Morten A. Karsdal and Kim Henriksen

Journal of Pharmacology and Experimental Therapeutics July 2017, 362 (1) 24-30; DOI: https://doi.org/10.1124/jpet.117.241281
Open Access
Nose-to-Brain Delivery
Zian Wang, Guojun Xiong, Wai Chun Tsang, Andreas G. Schätzlein and Ijeoma F. Uchegbu

Journal of Pharmacology and Experimental Therapeutics September 2019, 370 (3) 593-601; DOI: https://doi.org/10.1124/jpet.119.258152
You have access
Interaction between Bupropion and MDMA
Journal of Pharmacology and Experimental Therapeutics April 2015, 353 (1) 1; DOI: https://doi.org/10.1124/jpet.115.0415HIb
Open Access
(3S)‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine (IRL752) —a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent
S. Hjorth, S. Waters, N. Waters, J. Tedroff, P. Svensson, A. Fagerberg, M. Edling, B. Svanberg, E. Ljung, J. Gunnergren, S.L. McLean, B. Grayson, N.F. Idris, J.C. Neill and C. Sonesson

Journal of Pharmacology and Experimental Therapeutics September 2020, 374 (3) 404-419; DOI: https://doi.org/10.1124/jpet.120.000037
Open Access
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf, Todd Covey, Raquel Izumi, Bas van de Kar, Michael Gulrajani, Bart van Lith, Maaike van Hoek, Edwin de Zwart, Diana Mittag, Dennis Demont, Saskia Verkaik, Fanny Krantz, Paul G. Pearson, Roger Ulrich and Allard Kaptein

Journal of Pharmacology and Experimental Therapeutics November 2017, 363 (2) 240-252; DOI: https://doi.org/10.1124/jpet.117.242909
Open Access
SEP-363856, a Novel Psychotropic Agent with a Unique, Non-D₂ Receptor Mechanism of Action
Nina Dedic, Philip G. Jones, Seth C. Hopkins, Robert Lew, Liming Shao, John E. Campbell, Kerry L. Spear, Thomas H. Large, Una C. Campbell, Taleen Hanania, Emer Leahy and Kenneth S. Koblan

Journal of Pharmacology and Experimental Therapeutics October 2019, 371 (1) 1-14; DOI: https://doi.org/10.1124/jpet.119.260281
Open Access
p38α Regulates Expression of DUX4 in a Model of Facioscapulohumeral Muscular Dystrophy
L. Alejandro Rojas, Erin Valentine, Anthony Accorsi, Joseph Maglio, Ning Shen, Alan Robertson, Steven Kazmirski, Peter Rahl, Rabi Tawil, Diego Cadavid, Lorin A. Thompson, Lucienne Ronco, Aaron N. Chang, Angela M. Cacace and Owen Wallace

Journal of Pharmacology and Experimental Therapeutics September 2020, 374 (3) 489-498; DOI: https://doi.org/10.1124/jpet.119.264689
You have access
Targeting the Myofibroblast Genetic Switch: Inhibitors of Myocardin-Related Transcription Factor/Serum Response Factor–Regulated Gene Transcription Prevent Fibrosis in a Murine Model of Skin Injury
Andrew J. Haak, Pei-Suen Tsou, Mohammad A. Amin, Jeffrey H. Ruth, Phillip Campbell, David A. Fox, Dinesh Khanna, Scott D. Larsen and Richard R. Neubig

Journal of Pharmacology and Experimental Therapeutics June 2014, 349 (3) 480-486; DOI: https://doi.org/10.1124/jpet.114.213520
Open Access
Drug Discovery Strategies for SARS-CoV-2
Zeenat A. Shyr, Kirill Gorshkov, Catherine Z. Chen and Wei Zheng

Journal of Pharmacology and Experimental Therapeutics October 2020, 375 (1) 127-138; DOI: https://doi.org/10.1124/jpet.120.000123

Main menu

User menu

Search

Most read article(s)

Pages

Navigate

More Information

ASPET's Other Journals